DERM JOURNEY MEDICAL CORP

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, announced today that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.

Please click to register for the conference.

A replay of the fireside chat will be available shortly after the conference on the News and Events page of the Investors section of Journey Medical’s website, , for approximately 30 days after the meeting.

About Journey Medical Corporation

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit .

Company Contact:

Jaclyn Jaffe

(781) 652-4500

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839

    



EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on JOURNEY MEDICAL CORP

 PRESS RELEASE

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell o...

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monda...

 PRESS RELEASE

Journey Medical Corporation to Announce Second Quarter 2025 Financial ...

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today ann...

 PRESS RELEASE

Journey Medical Corporation Announces Expanded Payer Coverage for Emro...

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™ Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological co...

 PRESS RELEASE

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Journey Medical to Join Russell 2000® and Russell 3000® Indexes SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. eq...

 PRESS RELEASE

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Pres...

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch